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Abstract
Introduction: Given the high morbidity and mortality attributable to ventilator-associated pneumonia (VAP) in
intensive care unit (ICU) patients, prevention plays a key role in the management of patients undergoing
mechanical ventilation. One of the candidate preventive interventions is the selective decontamination of the
digestive or respiratory tract (SDRD) by topical antiseptic or antimicrobial agents. We performed a meta-analysis to
investigate the effect of topical digestive or respiratory tract decontamination with antiseptics or antibiotics in the
prevention of VAP, of mortality and of all ICU-acquired infections in mechanically ventilated ICU patients.
Methods: A meta-analysis of randomised controlled trials was performed. The U.S. National Library of Medicine’s
MEDLINE database, Embase, and Cochrane Library computerized bibliographic databases, and reference lists of
selected studies were used. Selection criteria for inclusion were: randomised controlled trials (RCTs); primary studies;
examining the reduction of VAP and/or mortality and/or all ICU-acquired infections in ICU patients by prophylactic
use of one or more of following topical treatments: 1) oropharyngeal decontamination using antiseptics or
antibiotics, 2) gastrointestinal tract decontamination using antibiotics, 3) oropharyngeal plus gastrointestinal tract
decontamination using antibiotics and 4) respiratory tract decontamination using antibiotics; reported enough data
to estimate the odds ratio (OR) or risk ratio (RR) and their variance; English language; published through June 2010.
Results: A total of 28 articles met all inclusion criteria and were included in the meta-analysis. The overall estimate
of efficacy of topical SDRD in the prevention of VAP was 27% (95% CI of efficacy = 16% to 37%) for antiseptics and
36% (95% CI of efficacy = 18% to 50%) for antibiotics, whereas in none of the meta-analyses conducted on
mortality was a significant effect found. The effect of topical SDRD in the prevention of all ICU-acquired infections
was statistically significant (efficacy = 29%; 95% CI of efficacy = 14% to 41%) for antibiotics whereas the use of
antiseptics did not show a significant beneficial effect.
Conclusions: Topical SDRD using antiseptics or antimicrobial agents is effective in reducing the frequency of VAP
in ICU. Unlike antiseptics, the use of topical antibiotics seems to be effective also in preventing all ICU-acquired
infections, while the effectiveness on mortality of these two approaches needs to be investigated in further
research.
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Infections that develop during intensive care unit (ICU)
stays represent a serious threat for critically ill patients
since they affect about 30% of patients who are admitted
to ICUs [1-6]. Ventilator associated pneumonia (VAP),
defined as a parenchymal infection of the lung occurring
in a patient who has been assisted by mechanical ventila-
tion within the past 48 hours [7], is the most common
infection acquired in the ICU [1]. VAP has a cumulative
incidence of 10 to 25% and accounts for approximately
25% of all ICU infections and 50% of the antibiotics pre-
scribed in ICU [8]. The impact of VAP is very high in
terms of morbidity, complicating the course of 8 to 28%
of the patients receiving mechanical ventilation [9,10],
prolonged ICU stays by an average of 4.3 to 6.1 days
[11-13] and attributable mortality rates that range from
5.8% to 27% [12-14]. Finally, VAP imposes excess costs
to health care institutions, but a precise evaluation of
such over-costs is difficult because it is dependent on dif-
ferent factors from one country to another, such as the
health care system, organization of the hospital and costs
of antibiotics [15].
Several studies strongly support the hypothesis that
colonization of the aerodigestive tract is primarily involved
in VAP and other ICU-acquired infections’ pathogenesis,
since micro-organisms move into the lower respiratory
tract or, through the gut, into the blood or regional lym-
phatics [16-22]. For these reasons selective decontamina-
tion of the aerodigestive tract represents a main objective
for infection prevention in ICU patients. Moreover, the
endotracheal tube plays a major role in the occurrence of
VAP by providing an abnormal continuum between the
u p p e ra i r w a ya n dt h et r a c h e aa n db ye s t a b l i s h i n gas u b -
glottic reservoir of secretions containing large amounts of
bacterial pathogens belonging to the oropharynx and the
stomach [23]. Secretions are aspirated into the trachea and
then disseminated into the lungs by the ventilator [24].
Given the high morbidity and mortality attributable to
VAP, prevention plays a key role in the management of
patients undergoing mechanical ventilation. Therefore, a
number of studies have investigated the effect of the selec-
tive decontamination of the digestive or respiratory tract
by topical antiseptic or antimicrobial agents in the reduc-
tion of VAP incidence; however, current guidelines from
the Center for Disease Control (CDC) for preventing
health-care-associated pneumonia, released in 2003 and
never updated, classify these practices as an “unresolved
issue” [16]. Moreover, this topic has also been analyzed in
previous meta-analyses and systematic reviews [25-31].
These reviews included trials conducted until 2006 and
demonstrated the effectiveness of topical antiseptics and
antibiotics in reducing VAP. However, five studies [32-36]
have been most recently published on the effectiveness of
antiseptics in the prevention of VAP, and four of these
[32-34,36] have come to opposite conclusions. Analo-
gously, one additional trial [37] has been published on the
role of topical antibiotics in the prevention of VAP that
found no significant effectiveness of the treatment.
All the previously mentioned meta-analyses investigated,
as a secondary outcome, the effects of topical antiseptics
and antibiotics in the prevention of overall mortality, and
they reported no significant effect of these interventions.
Since then, five studies investigating the effect of topical
antiseptics [32-36] and two of topical antibiotics [37,38]
on the reduction of overall mortality have been published.
Finally, several of the formerly quoted trials have investi-
gated the role of topical antiseptics and antibiotics in the
prevention of all ICU-acquired infections and have
reported controversial results, whereas no meta-analyses
have assessed this topic.
Therefore, we performed a meta-analysis with the
following aims: our primary goal was to update meta-
analyses on the effect of topical selective digestive (oro-
pharyngeal alone or including gastrointestinal tract) or
respiratory tract (subglottic area or trachea or aerosol
in the respiratory loop) decontamination (SDRD) with
antiseptics or antibiotics in the prevention of VAP in
mechanical ventilated ICU patients; and our secondary
goals were 1) to update meta-analyses on the effect of
topical SDRD with antiseptics and antibiotics on mortal-
ity in mechanical ventilated ICU patients, and 2) to per-
form the first meta-analysis on the effect of topical SDRD
with antiseptics or antibiotics on all ICU-acquired infec-
tions in mechanical ventilated ICU patients.
Materials and methods
Search strategy
A comprehensive systematic bibliographic search of med-
ical literature published until June, 2010 was conducted
to identify RCTs that assessed the effect of any type or
combination of topical antibiotics or antiseptics on the
prevention of pneumonia, all ICU-acquired infections
and mortality in adults requiring mechanical ventilation
in ICU.
The U.S. National Library of Medicine (MEDLINE),
Embase and The Cochrane Library computerized biblio-
graphic databases were used. In addition, we checked the
references lists from all retrieved studies and meta-ana-
lyses or systematic reviews already published, to ensure
that all studies could be identified. The following key
words in different combinations were used: “aerosolized
antibiotics”, “airway colonization”, “antibiotics”, “antimi-
crobial prophylaxis”, “antiseptic decontamination”,
“chlorhexidine”, “critical care”, “digestive decontamina-
tion”, “healthcare-associated infections”, “infection con-
trol”, “intensive care units”, “lower respiratory tract”,
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“nosocomial infection”, “oropharyngeal decontamina-
tion”, “pneumonia”, “povidone-iodine”, “prevention”,
“randomized controlled trials”, “respiratory infection”,
“selective decontamination”, “topical”, “ventilator-asso-
ciated pneumonia”.
Inclusion criteria
Articles that met the following criteria were included: (a)
RCTs; (b) primary studies, not re-analyses or reviews; (c)
examining the reduction of VAP and/or mortality and/or
all ICU-acquired infections in mechanical ventilated ICU
patients by prophylactic use of one or more of following
topical treatments: 1) oropharyngeal decontamination
using antiseptics or antibiotics, 2) gastrointestinal tract
decontamination using antibiotics, 3) oropharyngeal plus
gastrointestinal tract decontamination using antibiotics,
4) respiratory tract decontamination using antibiotics; (d)
reported enough data to estimate the odds ratio (OR) or
risk ratio (RR) and their variance; (e) English language; (f)
published through June 2010. Trials that used systemic
antibiotic prophylaxis were excluded.
Assessment of study quality
Two of the authors independently reviewed the studies
included in the meta-analysis to appraise the quality of the
individual trial using criteria developed for Study Protocol
and Data Analysis and Presentation by Chalmers et al.
[39] and the method of Jadad et al.[ 4 0 ] .T h eC h a l m e r s
et al. scale assigns a weighting factor to each item accord-
ing to whether it has been addressed completely (full
score), partially (half score) or not at all (no score). If an
item in the protocol was not applicable, the number of
possible points was reduced. The final score of each paper
was calculated as the total points scored divided by the
total number of points thought applicable to that study,
and two sub-scores regarding quality of Study Protocol
and Data Analysis and Presentation were also calculated
yielding a range from 0 to a full score of 1. The Jadad
score, ranging from 0 to 5 points, was assigned to the
included trials according to whether the investigators
described the study as randomized and double-blind,
reported the methods used to randomly assign patients
and blind the intervention, and reported the number of
withdrawals and dropouts and the reasons.
The readers discussed their evaluation and any
disagreements were resolved through discussion and re-
reading.
Data extraction
The following items were collected from each clinical
trial selected: a) study characteristics (authors, year of
publication, design, length of follow-up); b) patients’
characteristics (sample size in intervention and control
groups, duration of mechanical ventilation, disease
severity); c) VAP definitions and the incidence of VAP
in treatment and control groups; d) all ICU-acquired
infections’ definitions and the incidence in treatment
and control groups (we considered the number of
patients who have developed at least one nosocomial
infection including VAP); e) mortality in the ICU and/or
in-hospital; f) type, concentration and mode of delivery
of antimicrobial/antiseptics used, and control therapy.
Two independent reviewers extracted relevant trial
characteristics and interobserver agreements were
checked using the unweighted-kappa score [41]; differ-
ences between reviewers’ data were resolved by discus-
sion until a consensus was reached.
Statistical analysis
The pooled effects estimates were used to combine the
v a l u e sf r o mt h es i n g l es t u d i e sa n dw e r ee x p r e s s e da sR R
and the related 95% confidence intervals (CI). RR and CI
were obtained using the Mantel-Haenszel fixed effects
model [42], if the studies were homogeneous, and the
DerSimonian and Laird random effect model [43] in
cases with heterogeneity. Statistical heterogeneity was
assessed using Cochran Q and I
2 measure; a I
2 value
a b o v e2 5 %m a yb ec o n s i d e r e dl o wh e t e r o g e n e i t y ,av a l u e
above 50% and 75% were predefined as moderate and
high heterogeneity [44,45]. We preferred applying ran-
dom effects models’ results in case of I
2 equal or higher
than 50%.
Sensitivity analyses
The trials included in the meta-analysis differed consider-
ably in several factors such as study design (method of ran-
domization, blinding technique, modes of patients
recruitment), clinical heterogeneity of patients (characteris-
tics of participants, baseline disease severity), details of
intervention (type and mode of administration of drugs,
duration of treatment), and follow-up period, and subgroup
analyses were used to explore eventual heterogeneity. We
performed separate sensitivity analyses by grouping studies
that had similar characteristics, such as patient population
(medical or surgical or trauma or mixed critically ill
patients); topical selective decontamination of the digestive
tract or of the respiratory tract; associations of antimicro-
bial agents; antiseptic decontamination only with chlorhex-
idine; using placebo as comparator agent; double-blind
studies. At last, we performed a meta-analysis to determine
the potential impact of the quality of the studies on the
results, by pooling only studies with Jadad scores greater
than or equal to the median.
Finally, publication bias was explored by Egger’st e s t
[46,47] and Begg’s rank correlation test [48]. All statisti-
cal analyses were performed using Stata software, version
10 (Stata Corporation 4905 Lakeway Drive, College
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study’s findings was in accordance with the PRISMA
statement [50].
Results
Study characteristics
A total of 333 publications were identified as potentially
eligible for inclusion. Of these, 28 articles met all inclu-
sion criteria and were included in the meta-analysis. A
flow diagram providing the reasons for excluding the
articles from the meta-analysis is reported in Figure 1.
The agreement between the two researchers in the first
comparison was 89%, with a kappa score of 0.88, and
after discussion and detailed review of the articles was
complete (k = 1).
Tables 1 and 2 summarize information on the patients
and design of the included trials [32-38,51-71]. All trials
assessed mortality as an outcome, 25 VAP
[32-34,36,37,51-63,65-71] and 13 all ICU-acquired infec-
tions [37,38,51,52,54,56,58,60,64-68].
Data quality
The mean quality scores of the individual studies using
the Chalmers et al. scale was extremely variable, ranging
from 0.19 to 0.9 (mean = 0.64), for the Protocol from
0.25 to 0.97 (mean = 0.61) and for the Data Analysis
and Presentation from 0.13 to 0.88 (mean = 0.58). It
should be noted that none of the studies had a full
score, both for Protocol and Data Analysis and Presen-
tation. Almost all trials received full credit for descrip-
tion of daily amount and timing of therapeutic regimens
(93%), presentation of test statistic and P-value (93%)
and number of patients who withdrew and the reasons
why (89%), most trials reported description of relevant
variables in experimental and control group (86%), cri-
teria for patient selection (82%), methods for assuring
masking of randomization and to evaluate success of
masking (75%) and again start and stop dates (71%) and
analysis of comparability of the study groups (61%). A
few studies reported criteria for stopping the trial (39%),
CI (36%) and only 18% and 21% of the studies discussed
Figure 1 Flow chart of the published trials evaluated for inclusion in the meta-analysis.
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Authors Country Units of
treatment
T/C*
Interventions Delivery
mode
Daily amount and
timing
Outcomes Odds Ratio; 95%
Confidence Interval
Population
Treatment Control
AJ De Riso et
al. 1996 [51]
USA 173/180 0.12% CHX
† oral rinse +
Standard oral care
‡
Inert solution +
Standard oral care
‡
Oropharynx
§ For 30 s 2 times/d VAP
| In-hospital
mortality All ICU
¶-
acquired infections
0.35; 0.1 to 1.26 0.21;
0.05 to 0.94 0.36;
0.16 to 0.77
Cardiothoracic
ICU
¶
F Fourrier et al.
2000** [52]
France 30/30 0.2% CHX
† gel Standard oral care
‡ Dental and
gingival
surfaces
3 times/d VAP
| Mortality All
ICU
¶-acquired
infections
0.36; 0.13 to 1.01
0.43; 0.12 to 1.5 10;
2.59 to 42.21
Multidisciplinary
ICU
¶
S Houston et
al. 2002
†† [53]
USA 270/291 0.12% CHX
† oral rinse Listerine
‡‡ oral rinse Oropharynx
§,§§ 2 times/d For 10
days or until
extubation
VAP
| Mortality 0.48; 0.15 to 1.54
2.16; 0.54 to 8.53
Cardiothoracic
ICU
¶
F Fourrier et al.
2005 [54]
France 114/114 0.2% CHX
† gel Placebo gel Dental and
gingival
surfaces
3 times/d until 28
days
VAP
| ICU
¶ mortality
All ICU**-acquired
infections
1.08; 0.52 to 2.27
1.29; 0.81 to 2.06
1.06; 0.51 to 2.21
Multidisciplinary
ICU
¶
P Seguin et al.
2006
†† [55]
France 36/62 10% povidone-iodine oral
rinse+ aspiration of
oropharyngeal secretions
31 saline group
|| 31
control group
¶¶
Oropharynx
§
and
nasopharynx
Every 4 hours VAP
| ICU
¶ mortality 0.21; 0.07 to 0.64
0.65; 0.28 to 1.5
Surgical ICU
¶
P Segers et al.
2006 [56]
Netherland 485/469 0.12% CHX
† oral rinse and
nasal gel
Placebo oral rinse
and nasal gel
Oropharynx
§
and nasal
cavities
Oral rinse for 30 s
4 times/d; nasal gel
4 times/d
VAP
| In-hospital
mortality All ICU
¶-
acquired infections
0.59; 0.42 to 0.83 1.1;
0.39 to 3.15 0.58;
0.44 to 0.78
Cardiothoracic
ICU
¶
M Koeman et
al. 2006 [57]
Netherland 127/130 2% CHX
† in vaseline Vaseline Buccal cavity 4 times/d VAP
| ICU
¶ mortality 0.58; 0.31 to 1.09
1.12; 0.72 to 1.17
Multidisciplinary
ICU
¶
H Tantipong et
al. 2008
†† [32]
Thailand 102/105 Oral care
††† with 2% CHX
†
solution
Oral care***with
normal saline
solution
Oropharynx
§ 4 times/d VAP
| Mortality 0.58; 0.27 to 1.22
1;0.75 to 1.34
Multidisciplinary
ICU
¶ General
medical ward
F Bellissimo-
Rodrigues et
al. 2009 [33]
Brazil 98/96 0.12% CHX
† oral rinse Placebo oral rinse Buccal cavity 3 times/d until ICU
discharge
VAP
| ICU
¶ mortality 0.91; 0.39 to 2.06
1.06; 0.56 to 1.99
Multidisciplinary
ICU
¶
TS Panchabhai
et al. 2009
††
[34]
India 88/83 Cleansing
†††with 0.2% CHX
†
+ normal saline solution
Cleansing
†††with
0.01% PP
‡‡‡+ normal
saline solution
Oropharynx
§
and
hypopharynx
2 times/d until ICU
discharge or death
VAP
| In-hospital
mortality
0.88; 0.45 to 1.71
1.18; 0.96 to 1.46
Multidisciplinary
ICU
¶
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9Table 1 Characteristics of included randomized controlled trials on topical decontamination by antiseptics (Continued)
CL Munro et
al. 2009
†† [35]
USA 44/51 0.12% CHX
† oral swab Oral care (not
specified)
Buccal cavity 2 times/d In-hospital mortality 1.96; 0.67 to 5.87 Multidisciplinary
ICU
¶
F Scannapieco
et al. 2009 [36]
USA 116
§§§/59 Standard oral care
|||+ 0.12%
CHX
† oral rinse
Standard oral care
|||+
Placebo oral rinse
Buccal cavity 2 times/d VAP
| ICU
¶
mortality
¶¶¶
0.54; 0.23 to 1.25
1.01; 0.37 to 2.97
Trauma ICU
¶
* Treatment/control
†chlorhexidine gluconate
‡ mouth rinsing with bicarbonate isotonic serum followed by oropharyngeal aspiration four times a day
§ buccal, pharyngeal, gingival, tongue and tooth surfaces
| ventilator associated pneumonia
¶ intensive care units
**single blind randomized study
†† not blind randomized study
‡‡ phenolic mixture
§§patients received 15 ml of the experimental or the control drug preoperatively
||saline solution oral rinse followed by oropharyngeal aspiration
¶¶regimen without any instillation but with aspiration of oropharyngeal secretions only
*** patients received teeth brushing, oral secretions suctioning and the oropharyngeal mucosa rubbing with solution
††† oropharyngeal secretion suction and swab of the oral cavity, teeth, palate, buccal spaces, posterior pharyngeal wall and hypopharynx with normal saline solution followed by the same procedure with one of the
two study solutions
‡‡‡potassium permanganate
§§§two arms in treatment group: 58 patient received once daily chx and once daily placebo; 58 patients received twice daily chx
|||suction toothbrush twice a day and swabbing every four hours
¶¶¶treatment group: 97; control group: 49
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9Table 2 Characteristics of included randomized controlled trials on topical decontamination by antibiotics
Authors Country Units of
treatment
T/C*
Interventions Delivery mode Daily
amount and
timing
Outcomes Odds Ratio;
95%
Confidence
Interval
Population
Treatment Control
J Klastersky
et al. 1974
[58]
Belgium 43/42 Gentamicin (S) Normal saline (S) Trachea 3 times/d VAP
† Mortality All
ICU
§-acquired
infections
0.38; 0.17 to
0.86 1.36; 0.89
to 2.07 0.43;
0.16 to 1.14
Neurosurgical
ICU
§
K Unertl et
al.
| 1987 [59]
Germany 19/20 Polymyxin B+
Gentamicin (S)
Amphotericin B (Su)
No antimicrobial
prophylaxis
S applied orally, nasally and
enterally; Su in the
oropharynx
¶ (only T group)
4 times/d VAP
† Mortality 0.12; 0.02 to
0.84 0.91; 0.43
to 1.92
Multidisciplinary
ICU
§
C Brun
Buisson** et
al. 1989 [60]
France 36/50 Disinfection
††+
Polymyxin E+
Neomycin+ Nalidixic
acid (S)
Disinfection
†† Disinfection
†† of oropharynx
¶;
S applied orally and enterally
Disinfection
††
3 times/d; S 4
times/d
VAP
† ICU
§
mortality All ICU
§-
acquired infections
0.69; 0.19 to
2.59 0.94; 0.51
to 1.73 0.97;
0.35 to 2.63
Medical ICU
§
JM
Rodriguez-
Roldan et al.
1990 [61)
Spain 13/15 Disinfection
‡‡+
Polymyxin E+
Tobramycin or
Netilmicin+
Amphotericin B (P)
Disinfection
‡‡+ Inert
coloring substance (P)
Oropharynx
¶ 4 times/d VAP
† In-hospital
mortality
0.05; 0.0 to 0.77
0.92; 0.31 to
2.73
Multidisciplinary
ICU
§
J Pugin et al.
1991 [62]
Switzerland 25/27 Polymyxin B+
Neomycin+
Vancomycin (S)
Dextrose 5% (S) Unconscious patients: instilled
into retropharynx. Conscious
patients: keep the solution in
buccal cavity for 1 minute and
then to shallow it
Every 24 h VAP
† In-hospital
mortality
0.21; 0.08 to
0.52 1.08; 0.44
to 2.64
Surgical ICU
§
H Gastinne
et al. 1992
[63]
France 220/225 Colistin+ Tobramycin
+ Amphotericin B (S,
G)
Nonabsorbable calcium
salt (S, G)
G in oropharynx
¶; S enterally 4 times/d VAP
† In-hospital
mortality
1.3; 0.8 to 2.1
1.08; 0.89 to 1.3
Medical ICU
§
FB Cerra et
al. 1992 [64]
USA 25/21 Norfloxacin (Su) +
Nystatin (Su)
Cherry syrup (Su) Enterally Norfloxacin ×
3 Nystatin ×4
limited to 15
d
ICU
§ mortality All
ICU
§-acquired
infections
1.08; 0.64 to
1.84 0.67; 0.41
to 1.1
Surgical ICU
§
AM Korinek
et al. 1993
[65]
France 63/60 Polymyxin E+
Tobramycin+
Amphotericin B (S)
and P containing
same antibiotics plus
Vancomycin
Sterile water (S)
Carboxymethylcellulose
(P)
P in oropharynx
¶ S
administered enterally
4 times/d
limited to 15d
VAP
† ICU
§
mortality In-
hospital mortality
All ICU
§-acquired
infections
0.57; 0.34 to
0.97 0.57; 0.22
to 1.48 1.09;
0.59 to 2.01
0.56; 0.42 to
0.76
Neurosurgical
ICU
§
J Wiener et
al. 1995 [66]
USA 30/31 Polymyxin E+
Gentamicin+ Nystatin
(S, P)
Inert S and P P in oropharynx
¶ S
administered enterally
4 times/d VAP
† ICU
§
mortality All ICU
§-
acquired infections
1.03; 0.45 to 2.4
0.78; 0.45 to
1.34 0.82; 0.27
to 2.53
Multidisciplinary
ICU
§
B Quinio et
al. 1996 [67]
France 76/72 Polymyxin E+
Gentamicin+
Amphotericin B (Su,
P)
§§
Carboxymethylcell0ulose
(Su, P)
§§
G in oropharynx
¶ S
administered enterally
4 times/d VAP
† ICU
§mortality
All ICU
§-acquired
infections
0.49; 0.31 to
0.76 1.12; 0.75
to 1.67 0.6; 0.49
to 0.75
Multiple trauma
patients
admitted in
ICU
§
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9Table 2 Characteristics of included randomized controlled trials on topical decontamination by antibiotics (Continued)
DCJJ
Bergmans et
al. 2001 [68]
Netherland 87/139 Polymyxin E+
Gentamicin+
Vancomycin (O)
O without antibiotics
|| Buccal cavity Every 6 h
limited to 21d
VAP
† ICU
§
mortality In-
hospital mortality
All ICU
§-acquired
infections
0.37; 0.19 to
0.74 0.65; 0.35
to 1.21 0.71;
0.39 to 1.29
0.61;0.34 to 1.1
Multidisciplinary
ICU
§
GC Wood et
al. 2002 [69]
USA 20/20 Ceftazidime (A) Normal saline (A) Nebulizer connected to the
inspiratory loop
Every 12
hours for ≥
7d
VAP
† Mortality 0.47; 0.23 to
0.98 0.41; 0.06
to 2.41
Trauma ICU
§
I
Pneumatikos
et al. 2002**
[70]
Greece 31/30 Polymyxin E+
Tobramycin+
Amphotericin B (S)
Placebo S Subglottic area Continuous
infusion
VAP
† Mortality 0.37; 0.17 to
0.81 0.63; 0.14
to 2.7
Multiple trauma
patients
admitted in
ICU
§
M Koeman et
al. 2006 [57]
Netherland 128/130 CHX
¶¶ + Colistin in
vaseline
Vaseline Buccal cavity 4 times/d VAP† ICU
§
mortality
0.82; 0.41 to
1.63 1.02; 0.66
to 1.59
Multidisciplinary
ICU
§
M Kollef et
al. 2006 [71]
Multinational
study***
362/347 Iseganan (S) Placebo S Oropharynx
¶ For 2 min 6
times/d
limited to 14d
VAP
† ICU
§
mortality at 14d
0.86; 0.68 to
1.09 1.28; 0.87
to 1.88
Multidisciplinary
ICU
§
JA Claridge
et al. 2007
[37]
USA 53/52 Ceftazidime (A) Normal saline(A) Nebulizer connected to the
inspiratory loop
Every 12
hours for ≥
7d
VAP
† Mortality All
ICU
§ -acquired
infections
†††
0.98; 0.67 to
1.43 1.08; 0.63
to 1.85 1.71;
0.67 to 4.48
Trauma ICU
§
AM de Smet
et al. 2009**
[38]
Netherland 1904/1990 Polymyxin E+
Amphotericin B+
Tobramycin (P)
Standard oral care
‡‡‡ Buccal cavity (only T group) 4 times/d In-hospital
mortality ICU
§
mortality Mortality
at day 28 All ICU
§-
acquired
infections
§§§
0.95; 0.83 to
1.09 0.98; 0.84
to 1.15 0.96;
0.74 to 0.99
0.68; 0.53 to
0.86
Multidisciplinary
ICU
§
A, aerosol; g, gel; o, orabase; p, paste; s, solution; su, suspension
* treatment/control,
† ventilator associated pneumonia,
§ intensive care units,
| randomized study blinded for radiologic diagnosis,
¶ buccal, pharyngeal, gingival, tongue and tooth surfaces, ** not blind randomized
study,
†† disinfection with a povidone-iodine solution,
‡‡ disinfection with a 0.1% chlorhexidine solution,
§§ both groups received nasal and oropharyngeal toilet with povidone-iodine before each treatment or
placebo application,
|| two separate control groups: control a (78) was studied in the presence of patients receiving topical antimicrobial prophylaxis; control b (61) was studied in ICU where no topical antimicrobial
prophylaxis was used
¶¶ chlorhexidine gluconate, *** France, Spain, Switzerland, Netherland, UK, USA,
††† multi-drug-resistant infections,
‡‡‡ mouth rinsing with water 4 times a day and tooth brushing twice daily,
§§§ patients with at least
one episode of bacteremia or candidemia acquired in ICU.
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9beta error and side effects of treatment, respectively
(Table 3). With regard to the Jadad et al. criteria, the
mean score was 3.39 (median 4), most trials addressed
adequately the problems of withdrawals or dropouts
after randomization (74%) and were classified as double-
blinded (63%). Only eight trials [33,36,56,57,64,66,68,71]
had a full score on the Jadad et al. scale. It should be
noted that there has been improvement in study design
and reporting, since findings published more recently
tended to receive a higher quality rating.
Meta-analysis
Results of the meta-analyses that explored the effects of
topical use of antiseptics and antibiotics on the preven-
tion of VAP, mortality and all ICU-acquired infections
are shown in Table 4.
VAP
The incidence reduction of VAP in ICU patients by
topical SDRD was the main outcome measured. Results
from 11 trials [32-34,36,51-57] were available for the
analysis of the effects of topical digestive decontamina-
tion with antiseptics (Figure 2). The overall estimate of
efficacy of antiseptics in the fixed effects model was 27%
(95% CI of efficacy = 16% to 37%) and the I
2 statistic
test of homogeneity found a low heterogeneity across
the various studies (Q = 13.78 P = 0.18; I
2 = 27.4%).
Meta-analysis of the 15 trials that tested the effect of
topical SDRD by antibiotics [37,57-63,65-71] (Figure 2)
found a similar (36%) statistically significant reduction
in VAP rates (95% CI of efficacy = 18% to 50%) but the
test of homogeneity showed a moderate degree of statis-
tically significant heterogeneity (Q = 47.09 P <0 . 0 0 1 ;I
2
= 70.3%).
The results of the meta-analyses after limiting the ana-
lysis to high or low quality studies were not substantially
changed, although the efficacy was higher in the low
quality studies that used antiseptics and antibiotics as
Table 3 Distribution of studies by quality scoring values according to the Chalmers et al. method
Quality items Adequate*
Research protocol N. %
Description of inclusion and rejection criteria for patient selection (28) 23 82
Number and description of patients eligible not accepted (28) 16 57
Daily amount and timing of therapeutic regimen (28) 26 93
Physical appearance of placebo/control similar to the treatment (21) 16 76
Taste of placebo/control similar to the treatment (21) 10 48
Description and appropriate use of methods for assuring masking of randomization (28) 21 75
Patients masked treatment (27) 18 67
Observers masked to treatment (27) 17 63
Observers masked to results (28) 62 1
Prior estimate of sample size and power calculation (28) 15 54
Definition of criteria for stopping the trial (28) 11 39
Test of validity of randomization through description of relevant demographic and prognostic variables in experimental and control
group (28)
24 86
Methods used to evaluate success of masking (20) 15 75
Methods used to ascertain compliance to treatment (0) --
Laboratory tests to evaluate absorption or pharmacological effect of the treatment (16) 2 13
More than one observer evaluating subjective endpoints (23) 2 19
Data analysis and presentation
Start and stop dates (28) 20 71
Analysis of results of randomization through baseline comparability of the study groups (28) 17 61
Presentation of test statistics and P-value (28) 26 93
Discussion of ß error in negative trials (17) 31 8
Calculation of estimate of variance and/or confidence limits of trials endpoints (28) 10 36
Regression/correlation analysis (25) 12 48
Overall assessment of quality of statistical analysis (28) 14
Number of patients who withdrew and the reasons why (28) 25 89
Ways withdrawals were handled (23) 14
Side effects reported and analyzed (28) 62 1
Analysis of subgroups not specified at the beginning of the study (retrospective analysis) (28) 2 7
Number of studies for which item was applicable in parenthesis
*Completely addressed the issue
Pileggi et al. Critical Care 2011, 15:R155
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Page 9 of 19Table 4 Meta-analysis results of effectiveness of topical decontamination in reducing VAP, mortality and all ICU-acquired infections
Antiseptics Antibiotics
VAP
† Prevention No.
Studies
No.
Patients
Overall Risk
Ratio
(Efficacy,
%)
95% Confidence
Interval (Efficacy
interval,%)
Heterogeneity
Test (Q; P;I
2,
%)
No.
Studies
No.
Patients
Overall Risk
Ratio (Efficacy,
%)
95% Confidence
Interval (Efficacy
interval, %)
Heterogeneity
Test (Q; P;I
2,
%)
All studies 11 3,258 0.73 (27) 0.63 to 0.84 (16 to 37) 13.78; 0.18; 27.4 15 2,463 0.64 (36) 0.5 to 0.82 (18 to 50) 47.09; <0.001;
70.3
High quality 6 2,161 0.77 (23) 0.66 to 0.9 (10 to 34) 4.62; 0.46; 0 11 2,249 0.69 (31) 0.54 to 0.89 (11 to 46) 34.66; <0.001;
71.2
Low quality 5 1,097 0.6 (40) 0.44 to 0.82 (18 to 56) 8.99; 0.06; 55.5 4 214 0.35 (65) 0.14 to 0.86 (14 to 86) 5.64; 0.13; 46.8
Only specialty surgery ICU* 4 1,966 0.52 (48) 0.38 to 0.71 (29 to 62) 3.55; 0.31; 15.5 3 260 0.4 (60) 0.2 to 0.8 (20 to 80) 5.64; 0.06; 64.6
Only trauma patients NA
‡ - -- - 4 354 0.6 (40) 0.38 to 0.93 (7 to 62) 8.2; 0.04; 63.4
Mixed ICU* 6 1,117 0.82 (18) 0.68 to 1.00 (0 to 32) 5.77; 0.33; 13.3 6 1,318 0.7 (30) 0.46 to 1.05 (-5 to 54) 13.41; 0.02; 62.7
Only double blinded studies Same high quality meta-analysis 12 2,277 0.67 (33) 0.52 to 0.87 (13 to 48) 39.53; <0.001;
72.2
Not double blinded studies Same low quality meta-analysis 3 186 0.44 (56) 0.21 to 0.92 (8 to 79) 2.83; 0.24; 29.3
Using same antibiotics
combination:
Cyclic peptide +
aminoglycoside + polyene
antifungal drug
- - -- - 6 782 0.60 (40) 0.35 to 1.04 (-4 to 65) 22.21; <0.001;
77.5
Vancomycin + other
antimicrobial agents
- - -- - 3 401 0.43 (57) 0.24 to 0.78 (22 to 76) 5.3; 0.07; 62.3
Digestive tract decontamination
with antibiotics
- - -- - 1 1 2,172 0.67 (33) 0.5 to 0.9 (10 to 50) 35.99; <0.001;
72.2
Respiratory tract
decontamination with antibiotics
- - -- - 4 291 0.54 (46) 0.3 to 0.97 (3 to 97) 9.67; 0.02; 69
Mortality
All studies 12 3,224 1.1 (-10) 0.98 to 1.24 (-24 to 2) 9.89; 0.54; 0 17 6,403 1.02 (-2) 0.93 to 1.13 (-13 to 7) 9.82; 0.88; 0
High quality 6 2,132 1.09 (-9) 0.9 to 1.32 (-32 to 10) 3.59; 0.61; 0 12 2,295 1.06 (-6) 0.94 to 1.2 (-20 to 6) 8.55;0.66;0
Low quality 6 1,192 1.11 (-11) 0.96 to 1.29 (-29 to 4) 6.27; 0.28; 20.3 5 4,108 0.97 (3) 0.84 to 1.12 (-12 to 16) 0.38; 0.98; 0
Only ICU* mortality 8 1,751 1.08 (-8) 0.92 to 1.26 (-26 to 8) 4.9; 0.67; 0 14 5,878 1.01 (-1) 0.9 to 1.12 (-12 to 10) 9.39; 0.74; 0
Only in-hospital mortality 4 1,573 0.95 (5) 0.95 to 1.37 (-37 to 5) 4.74; 0.19; 36.7 6 4,768 0.98 (2) 0.88 to 1.09 (-9 to 12) 2.43; 0.79; 0
Only double blinded studies Same high quality meta-analysis 13 2,323 1.06 (-6) 0.94 to 1.2 (-20 to 6) 8.59; 0.74; 0
Not double blinded studies Same low quality meta-analysis 4 4,080 0.97 (3) 0.84 to 1.12 (-12 to 16) 0.37; 0.95; 0
Using same antibiotics
combination:
Cyclic peptide +
aminoglycoside + polyene
antifungal drug
-- - - 7 4,676 0.99 (1) 0.89 to 1.09 (-9 to 11) 2.62; 0.85; 0
Vancomycin + other
antimicrobial agents
- - -- - 3 401 0.89 (11) 0.59 to 1.35 (-35 to 41) 1.06; 0.59; 0
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9Table 4 Meta-analysis results of effectiveness of topical decontamination in reducing VAP, mortality and all ICU-acquired infections (Continued)
Digestive tract decontamination
with antibiotics
- - -- - 1 3 6,112 1.01 (-1) 0.92 to 1.12 (-12 to 8) 6.72; 0.87; 0
Respiratory tract
decontamination with antibiotics
- - -- - 4 291 1.17 (-17) 0.85 to 1.61 (-61 to 15) 2.36; 0.5; 0
All ICU*-Acquired infections
All studies 4 1,595 1.02 (-2) 0.41 to 2.51 (-151 to 59) 20.14; <0.001;
85.1
9 4,774 0.71 (29) 0.59 to 0.86 (14 to 41) 18.62; 0.02; 57
High quality 3 1,535 0.59 (41) 0.47 to 0.76 (0.24 to 53) 3.9; 0.14; 48.7 7 794 0.64 (36) 0.56 to 0.73 (27 to 44) 7.57; 0.27; 20.7
Low quality NA
‡ - -- - 2 3,980 0.89 (11) 0.52 to 1.52 (-52 to 48) 6.57; 0.01; 84.8
Only specialty surgery ICU* 2 1,307 0.55 (45) 0.43 to 0.72 (28 to 57) 1.19; 0.28; 16 4 340 0.71 (29) 0.45 to 1.11 (-11 to 55) 12.15; 0.007;
75.3
Mixed ICU* 2 288 3.02 (-202) 0.34 to 27.12
(-2.61 to 66)
8.2; 0.004; 87.8 3 4,181 0.7 (30) 0.59 to 0.85 (15 to 41) 0.65; 0.72; 0
Using same antibiotics
combination:
Cyclic peptide +
aminoglycoside + polyene +
antifungal drug
- - -- - 3 4,103 0.66 (34) 0.57 to 0.76 (24 to 43) 1.91; 0.38; 0
Vancomycin + other
antimicrobial agents
- - -- - 2 349 0.53 (43) 0.44 to 0.74 (26 to 56) 0.07; 0.79; 0
Digestive tract decontamination
with antibiotics
- - -- - 7 4,584 0.7 (30) 0.58 to 0.84 (16 to 42) 14.11; 0.03; 57.5
Respiratory tract
decontamination with antibiotics
- - -- - 2 190 0.87 (13) 0.22 to 3.35 (-235 to 78) 3.95; 0.05; 74.7
* Intensive care units,
† ventilator associated pneumonia,
‡not applicable because only one study belongs to this group.
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9compared to that found in the high quality trials both
with antiseptics and antibiotics agents.
Sensitivity analyses were conducted to determine
whether the efficacy of chlorhexidine was correlated to
dose (0.12% vs 0.20% or 2% preparations; twice a day
application vs three or four applications a day). The
results showed a 31% significant incidence reduction of
VAP (95%CI of efficacy = 3% to 51%; Q = 0.91 P = 0.63;
I
2 = 0%) even using the lowest concentration of chlor-
hexidine (twice a day application of 0.12% chlorhexidine
gluconate) (data not shown).
Pooled analysis after restriction to specific settings
showed that, both for antiseptics and antibiotics, the
highest efficacy was found in specialty surgical ICUs and
the lowest in mixed ICUs.
The separate meta-analyses involving digestive tract
decontamination by antibiotics showed lower efficacy as
compared to respiratory tract decontamination by
antibiotics.
Finally, we tested the effectiveness of similar combina-
tions of topical antibiotics on VAP prevention and only
in the trials that used vancomycin combined with other
antimicrobial agents, a significant VAP reduction was
found. Overall, low heterogeneity was revealed in almost
all sensitivity analyses involving antiseptics, whereas a
significant heterogeneity remained in the results among
trials on antibiotic prophylaxis of VAP.
Mortality
In none of the meta-analyses conducted on mortality
was a significant effect found.
All ICU-acquired infections
Four studies on antiseptics contributed to the analysis of
all ICU-acquired infections prevention [51,52,54,56]
(Figure 3) and indicated no statistically significant
Figure 2 Meta-analysis of the effectiveness of topical SDRD in the prevention of VAP in ICU.( a) Decontamination by antiseptics. (b)
Decontamination by antibiotics. * Risk ratio;
‡ confidence interval;
† ventilator associated pneumonia.
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Page 12 of 19beneficial effect of the experimental treatment (efficacy
= -2%; 95% CI of efficacy = -151% to 59%; Q = 20.14 P
< 0.001; I
2 = 85.1%). If the analysis was restricted to
high quality studies, the efficacy to prevent all ICU-
acquired infections was 41% (95% CI of efficacy = 24%
to 53%) and a reduction of heterogeneity among studies
became evident (Q = 3.9 P = 0.14; I
2 = 48.7%). Similarly,
studies involving only specialty surgery ICU showed a
significant decrease of all ICU-acquired infections, with
a value of 45% (95% CI of efficacy = 28% to 57%).
Nine trials that tested antibiotic prophylaxis were
available for the analysis of all ICU-acquired infections
[37,38,58,60,64-68] (Figure 3) and a significant decline
in all ICU-acquired infection rate was demonstrated
(efficacy = 29%; 95% CI of efficacy = 14% to 41%; Q =
18.62 P = 0.02; I
2 = 57%). Sensitivity analyses proved an
efficacy of the treatment only in the high quality studies
when only the digestive tract decontamination was
taken into account, when the analysis was restricted to
mixed ICU, and to similar conclusion led the meta-ana-
lyses limited to research that used the same antibiotic
combinations, cyclic peptide plus aminoglycoside plus
polyene antifungal drug and vancomycin plus other anti-
microbial agents. In most restricted analyses, heteroge-
neity disappeared.
Other VAP related outcomes
VAP is important not only if it increases mortality, but
also the length of hospital stay, duration of mechanical
ventilation, use of antibiotics, quality of life and the
length of ICU stay. We tentatively tried to extract data
on some of these outcomes from the included trials and
we could perform meta-analyses on the duration of
mechanical ventilation and length of ICU stay. However,
data on duration of mechanical ventilation were
Figure 3 Meta-analysis of the effectiveness of topical SDRD in the prevention of all ICU-acquired infections.( a) Decontamination by
antiseptics. (b) Decontamination by antibiotics. * Risk ratio;
‡ confidence interval;
† intensive care units.
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Page 13 of 19available only in two antiseptics trials [36,55] and in four
antibiotics trials [62,67,69,70] and gave a non-significant
effect with a mean difference (MD) for antiseptic use of
-0.19 days (95% CI = -0.46 to 0.07; Q = 0.07 P = 0.79; I
2
= 0%) and for antibiotic use of -0.12 days (95% CI =
-0.34 to 0.11; Q = 0.54 P =0 . 9 1 ;I
2 =0 % ) .D a t ao n
length of ICU stay were available in three studies using
antiseptics [36,55,56] and in six studies using antibiotics
[60,62-64,67,69]. Pooled analyses of these trials did not
show an influence on the mean difference of length of
ICU stay both for antiseptics (MD = -0.7 days; 95% CI =
-0.19 to 0.04; Q = 0.4 P =0 . 8 1 ;I
2 = 0%) and antibiotics
(MD = -0.34 days; 95% CI = -0.73 to 0.05; Q = 27.67 P
< 0.001; I
2 = 81.9%).
Publication bias
Funnel plots showed no significant asymmetry for stu-
dies exploring the preventive role of antiseptics and of
antibiotics.
Discussion
VAP
The major finding of the present meta-analysis provides
support to the observation that topical antiseptic or
antibiotic SDRD plays a significant role as a protective
factor against the development of VAP.
Chlorhexidine has been used as a degerming agent in
all but one antiseptic trial, because it has a high level of
antibacterial, antiviral and antifungal activity, it is vir-
tually free of adverse effects [72] and it is an inexpensive
solution. Seguin et al. used povidone-iodine, another
antiseptic agent that has high, rapid and persistent activ-
ity on Gram-negative and Gram-positive bacteria
[73,74], and it is simple and safe to use [75]. Our results
do not allow us to determine which of the two antisep-
tics has a greater effect, but confirmed the preventive
role of antiseptics against VAP. To find the best disin-
fectant further studies are needed comparing povidone-
iodine and chlorhexidine in preventing VAP in “head to
head” trials.
The findings of this pooled analysis are consistent
with the relatively strong protective association observed
between antiseptic oropharyngeal decontamination and
the risk of VAP observed in previous meta-analyses
[25-28].
Since the pathogenesis of VAP is related to contami-
nation of the aero-digestive tract, our meta-analyses on
antibiotics were conducted combining data on topical
digestive and respiratory tract decontamination and our
findings showed a significant protective effect of the
antibiotics. This result persisted when we considered
separately the digestive and the respiratory tract decon-
tamination, suggesting that any of these two ways of
decontamination may be used. Only two studies [57,70]
classified VAP according to time of onset in early and
late-onset [76]; therefore, we have not performed a sen-
sitivity analysis on this issue.
Comparisons with the results of previous meta-ana-
lyses are very difficult since the inclusion criteria used
were different. Indeed, Liberati et al. [31] did not make
any restriction on the type of respiratory tract infections
(RTIs), combining trials on pneumonia and tracheo-
bronchitis in ICU patients, nor on unpublished RCT or
on language, whereas they restricted inclusion to diges-
tive decontamination by antibiotics only. The results of
Liberati et al. showed a significant protective effect on
RTIs.
Chan et al. [27] did not reach our conclusions since
their results suggested no significant protective effect of
topical antibiotic prophylaxis on VAP. Indeed, the meta-
analysis of Chan et al. had only two studies [68,71] in
common with ours, and pooled 1,098 patients, whereas
the present meta-analysis could take into account a lar-
ger sample size (2,463 patients). Finally, Falagas et al.
[30], who took into account only the effect of adminis-
tration of antimicrobial agents via the respiratory tract,
concluded that pneumonia occurred significantly less
often in the prophylaxis arm compared to the compari-
son arm. Our sub-analysis on trials that tested respira-
tory tract decontamination confirms these results, even
i ft h es a m p l ea n a l y z e di sd i f f e r e n tb e c a u s ew ei n c l u d e d
only pneumonia occurring in patients assisted by
mechanical ventilation; therefore, we excluded the trials
of Greenfield et al. [77] because data on colonization
only was reported and of Klick et al. [78] for incomplete
data on outcomes. Moreover, we excluded non-rando-
mized trials [79] and abstracts [80], and included one
study in which the preventive strategy was topical
decontamination in the subglottic area [70], and a recent
trial that tested prophylactic administration of aeroso-
lized ceftazidime [37].
Mortality
In the present meta-analysis neither antibiotic nor anti-
septic topical decontamination influenced overall mor-
tality, and the results did not substantially differ in the
separate meta-analyses performed according to different
quality and study design or details of intervention. Lib-
erati et al., in previously published meta-analysis, exam-
ining the prophylactic use of antibiotics, have shown
efficacy in reducing mortality when topical decontami-
nation was combined with intravenous antibiotic admin-
istration, whereas, in line with our results, topical
prophylaxis alone was not effective. No former meta-
analyses on antiseptics or antibiotics [27-29,31] showed
a significant beneficial effect on mortality.
These results could be due to lack of an effect of
administration of topical agents on mortality since in
only one trial that used antiseptic decontamination [51],
Pileggi et al. Critical Care 2011, 15:R155
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Page 14 of 19and in no antibiotic trials [37,38,57-71], was a significant
reduction in mortality found. Another possible explana-
tion was that in most of the trials mortality was a sec-
ondary outcome and data accuracy could be lower than
primary outcome; therefore, analysis combining these
data could have failed to show an effect of experimental
treatment. Also, in our case the overall sample size was
small and, therefore, could have limited the interpreta-
tion of the effect on mortality. Another possible expla-
nation can be related to our inability to distinguish the
role of the topical SDRD on the occurrence of early and
late-onset VAP. It has beend e m o n s t r a t e dt h a tV A P
related mortality is restricted mainly to patients with
late-onset VAP; it is only marginally reduced with
appropriate empirical antibiotic treatment [14]. In the
same study the authors report that the prophylactic
regimen they used, that is, the universal use of continu-
ous aspiration of subglottic secretions, was recognized
to be a reducing and delaying factor for VAP. Therefore,
we may hypotheses that if the topical SDRD is also par-
ticularly effective only on the reduction of early-onset
VAP, its role on late-onset VAP related mortality may
be marginal. Trials allowing data extraction on the
occurrence of early and late-onset VAP separately are
strongly needed.
All ICU-acquired infections
To the best of our knowledge, this is the first meta-ana-
lysis aimed at the assessment of the effectiveness of
topical SDRD on the incidence of all ICU-acquired
infections.
Our results have shown the effectiveness of topical
SDRD both with antiseptics, although only in the sensi-
tivity analyses restricted to high quality studies and to
those involving only specialty surgery ICU, and
antibiotics.
These achievements confirmed what we expected
because colonization is a prerequisite for the develop-
ment of infections that frequently arises from the endo-
genous flora in the oropharyngeal and intestinal tract;
therefore, healthcare-associated infections were poten-
tially preventable through the suppression of coloniza-
tion of the digestive and/or the respiratory tract. Also,
nosocomial pneumonia is the second most common
healthcare-associated infections (HAI) and the most fre-
quently acquired infection in the ICU, so all ICU-
acquired infections could be reduced secondarily from a
VAP prevention.
Resistance to antiseptic and antimicrobial agents
Considering the importance of antibiotic-resistance in
ICUs, we focused our interest on topical administration
since it has been reported that it is more frequent when
a combination of topical plus systemic antibiotics was
used [81,82] rather than only topical antibiotics [38,83].
Anyway, the biggest criticism even against topical SDRD
is the emergence of resistant strains. This issue has been
only marginally investigated in most of the studies
included in the meta-analysis. The majority of the trials
using antibiotics [37,38,57,59,61,62,64,68,69] found no
increase in infections caused by antibiotic-resistant
organisms, at least during the relatively short period of
studies, whereas a trend towards increased colonization
of patients by resistant microbial strains was reported
[58,66,67]. This increase was not found in studies using
antiseptics [37,51,52,57]. On the basis of these results, a
long-term increase in the occurrence of HAIs sustained
by resistant strains as a result of topical SDRD with
antibiotics cannot be excluded, and this issue warrants
cautious attention in further studies. However, it should
be pointed out that routine five-year use of selective
digestive decontamination was not associated with
increased antimicrobial resistance rates [83]. This find-
ing allows us to suggest an analogous result with the
use of long-term topical SDRD at least in ICU with low
baseline resistance rates.
Strengths and limitations of the study
The strengths of the present meta-analysis include the
considerable number of studies and subjects included
a sw e l la st h ea c c e p t a b l em e t h o d o l o g i cq u a l i t yo ft h e
studies on which the analysis is based. It is well-known
that the quality assessment of the primary studies has
been identified as one of the most important steps of
the peer-review process [84]. This comes from the
consideration that studies of poor quality may yield
information that is not valid; therefore, the inclusion
of studies with invalid information in a meta-analysis
can make the conclusion of the meta-analysis invalid.
Therefore, taking the quality of studies into account in
a meta-analysis has the potential to enhance the valid-
ity of a meta-analysis because quality is implicitly a
measure of validity [85]. Moreover, the evaluation of
the quality of the studies in a meta-analysis may con-
tribute to point out limitations in published studies
and suggest ways to improve the methodology of stu-
dies in further research. In this meta-analysis the qual-
ity of the RCTs was good with regard to the various
methodological aspects of the research protocol (for
example, description of therapeutic regimen, criteria
for patient selection, randomization, blinding) while
the main shortcomings were related to the overall
assessment of the statistical methods and presentation
of data. Limitations of the present meta-analysis study
include the heterogeneity between the studies with
respect to patient populations that had a different pro-
file of risk factors; different medications used, particu-
larly in antibiotic trials, in the choice of the
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Page 15 of 19antimicrobial agents or their associations or the deliv-
ery mode; different approaches for the control arms
and different outcome definitions. Moreover, among
our inclusion criteria there was restriction to studies
published in English. This is a controversial issue,
since some argue that authors are more likely to report
positive results in international journals and negative
results in local journals, as demonstrated by Egger et
al. [86]. Language restriction could, therefore, intro-
duce bias in the results of the meta-analysis [87,88].
However, there has also been evidence that studies
published in local journals may be of lower methodo-
logical quality, as reported by Sterne et al.[ 8 9 ] ,a n d
this would be in favor of their exclusion. We have also
performed a search without language restriction and it
would have led to the inclusion of two more papers
[90,91]. Vogel et al. [90] was excluded because it was
n o taR C T ,w h i l ew eh a v er e p e a t e dt h em e t a - a n a l y s e s
of topical SDRD by antibiotics on VAP prevention and
on mortality by entering Rathgeber et al. [91] and the
results did not alter our conclusions. Indeed, the over-
all estimate of efficacy of antibiotics on VAP preven-
tion was 37% (95% CI of efficacy = 20% to 51%) and
the meta-analysis on mortality showed no significant
effect (efficacy = -2%; 95% CI of efficacy = -12% to
7%). These results were confirmed in the sensitivity
analyses involving only upper respiratory tract decon-
tamination with antibiotics (data not shown). There-
fore, we believe that our strategy is not prone to
substantial bias or to low robustness in the overall
results. Finally, the findings are affected by the limita-
tions of the individual trials included. According to the
mentioned limitations, the results of the meta-analysis
must be interpreted with caution; however, the careful
examination of possible sources of heterogeneity con-
tributed to assess the methodologic quality of research,
and to identify potential biases, data gaps, and sugges-
tions for future research.
Conclusions
I nc o n c l u s i o n ,d e s p i t et h ea b o v el i m i t a t i o n s ,w et h i n k
that our results prove that topical SDRD using antisep-
tics or antimicrobial agents is effective in reducing the
frequency of VAP in ICU. Unlike antiseptics, the use of
topical antibiotics seems to be effective also in prevent-
ing all ICU-acquired infections, while the effectiveness
on mortality of these two approaches needs to be inves-
tigated in further research. Also, further research is
essential to compare different preventive protocols in
ICU patients, such as the “head to head” comparison of
topical antiseptics and antibiotics, the oral cavity decon-
tamination only compared to the whole digestive tract,
or the decontamination of the airways to the digestive
tract. Finally, a more careful assessment of the cost-
effectiveness of preventive interventions used and a
more systematic evaluation of issues related to the
emergence of drug resistance are necessary.
Key messages
■ VAP is related to a high rate of morbidity, compli-
cations, prolonged ICU stay and mortality in patients
receiving mechanical ventilation.
■ Colonization of the aerodigestive tract is primarily
involved in VAP’sp a t h o g e n e s i sa n dr e p r e s e n t sa
main objective for prevention.
■ Topical SDRD using antiseptics or antibiotics is
effective in reducing the incidence of VAP in ICU.
■ Topical SDRD using antibiotics is effective in
reducing the incidence of all ICU-acquired
infections.
■ Further research is essential to compare different
preventive protocols in ICU patients and to assess
the cost-effectiveness of preventive intervention
used.
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